ALSO NOTED: FDA delays FluMist decision; Experts to meet on Tysabri for Crohn's; New biotech campus planned; and much more...

> The FDA says that it will delay a decision on extending the age range allowed for FluMist until MedImmune brings its UK facility into compliance. Regulators cited the facility last March. Regulators also say that their warning shouldn't disrupt the delivery of MedImmune's nasal flu vaccine. Report

> An FDA advisory panel will meet on July 31 to review the case for using Tysabri against Crohn's disease. Report

> The Harnett Forward Together Committee has completed a blueprint for a 130-acre biotech campus in North Carolina. Report

> Ranbaxy Laboratories has acquired from Bristol-Myers Squibb Company the U.S. rights to a group of 13 dermatology products. Release

> The EU has published the first comprehensive evaluation of the contribution of modern biotechnology to major European Union policy goals. The report found that modern biotechnology accounts for up to 1.69 percent of the EU economy. Release

> An international team of investigators working on a specially funded project have found that antibodies extracted from bird flu victims provided immunity to mice later infected with H5N1. Report

And Finally… A Harvard Medical School researcher has joined with two New York hedge funds to create a new million-dollar annual award for the best new thinking in cancer research. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.